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Many patients on chronic warfarin therapy are undergoing surgery for permanent pacemakers and
implantable deﬁbrillators, collectively known as cardiac implantable electronic device (CIED). The
perioperative management of anticoagulation in these patients is a challenging clinical situation that
requires balance between the risk of acute thrombosis and perioperative hemorrhage. This issue
however, is inadequately addressed in the guidelines published by professional organizations.
Increasing evidence suggests that temporarily interrupting anticoagulation is associated with a small
but real thromboembolic risk, whereas cessation of warfarin with heparin bridging anticoagulation
frequently leads to a higher incidence of pocket hematoma. Continuing warfarin with a therapeutic
international normalized ratio appears to be a safe and cost-effective approach for CIED surgery in most
patients with moderate to high thromboembolic risk. An algorithm is proposed for the practical
management of anticoagulation and antiplatelet therapy in these patients during the perioperative
period.
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The optimal management of perioperative anticoagulation
in patients on warfarin therapy undergoing cardiac implan-
table electronic device (CIED) surgery is not yet established.rt Rhythm Society. Published by E
thPartners Medical Group,
kson Street, Saint Paul, MN
(D.W. Zhu MD, FACC, FHRS).Neither the recent American Heart Association/American College
of Cardiology nor European Society of Cardiology guidelines
mentioned device surgery in patients on chronic anticoagulation
therapy. The 2008 guidelines from the American College of Chest
Physicians (ACCP) have recommended the use of bridging antic-
oagulation with therapeutic dose of subcutaneous low-molecular-
weight heparin (LMWH) or intravenous heparin in patients with
mechanical heart valves, atrial ﬁbrillation, or venous thromboem-
bolism who are at moderate or high risk for thromboembolic
events [1]. This recommendation, however, was largely based onlsevier B.V. All rights reserved.
Table 1
Risk stratiﬁcation for perioperative thromboembolism.
Risk group Mechanical heart valve Atrial ﬁbrillation VTE
High Mitral valve prosthesis CHADS2 score of 5 or 6 VTE r3months
Stroke or TIAr3 months Severe thrombophilia (deﬁciency of protein C, protein S or antithrombin; antiphospholipid
Stroke or TIAr6 months Rheumatic valvular heart disease
Moderate Aortic valve prosthesis CHADS2 score of 2 to 4 VTE within3–12 months
Nonsevere thrombophilia (e.g., heterozygous factor Leiden)
Recurrent VTE
Active cancer
Low CHADS2 score of 0 to 1 VTE 412 months and no other risk factors
CHADS2¼congestive heart failure, hypertension, ageZ75 years, diabetes mellitus, and stroke or transient ischemic attack.
TIA¼transient ischemic attack, VTE¼venous thromboemolic event.
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surgery to be a procedure associated with an increased bleeding
risk during perioperative antithrombotic administration [2]. CIED
implantation in which separation of infraclavicular fascial layers
and lack of suturing of unopposed tissues within device pocket
may predispose to hematoma development. However, the updated
guidelines did not provide speciﬁc recommendations on the
management of this patient population. Recent surveys in Canada
and United Kingdom revealed a lack of consensus among the CIED
implanting physicians on whether to withhold anticoagulation
and whether to use bridging therapy [3,4]. As increasing data are
emerging during the last decade, we are here to provide an
updated literature review and to offer our suggestions on the
practical management of this important clinical issue.2. Perioperative risk assessment of thromboembolism
The current thromboembolic risk stratiﬁcation is largely based
on indirect evidence from studies outside of the perioperative
setting involving patients with a mechanical heart valve, chronic
atrial ﬁbrillation or venous thromboembolism who either did not
receive anticoagulation ( i.e., placebo-treated group in atrial ﬁbrilla-
tion trials) or received less-effective treatment (e.g., aspirin-treated
group in mechanical heart valve trials) [2]. Table 1 is a simpliﬁed
risk stratiﬁcation scheme for perioperative thromboembolism.
Patients are classiﬁed as high risk (annual risk410%), moderate
risk (annual risk 5% to 10%), and low risk (annual risko5%) for
thromboembolism. An estimate of individual patient risk for perio-
perative thromboembolism is subjective but should consider both
the baseline risk and the individual patient factors. For patients who
are already on chronic warfarin therapy, most of them should have
been considered by their physicians as moderate to high risk for
thromboembolism.3. Current management options
Three strategies in the management of anticoagulation during
the perioperative period of CIED surgery are frequently used in
the current clinical practice.
In the ﬁrst strategy, device implantation in patients on warfarin
therapy is often postponed until the International Normalized
Ratio (INR) has decreased to a nontherapeutic or ‘‘safe’’ level by
withholding warfarin, with or without administration of coagula-
tion factors (fresh frozen plasma) or vitamin K. Several days may
be needed to reestablish therapeutic anticoagulation after the
procedure. Although the period of subtherapeutic anticoagulation
is short, exposing patients to potential thromboembolic compli-
cations is a concern, especially in those deemed to be moderate or
high risk.In the second strategy, bridging therapy with intravenous
heparin or subcutaneous LMWH is used to minimize the time before
and after the procedure during which INR is subtherapeutic in
patients with moderate to high risk of thromboembolic events.
Bridging therapy, however, has been associated with an increased
incidence of pocket hematoma and other bleeding complications,
higher costs, and complexity of procedure scheduling.
In the third strategy, CIED surgery is performed without
cessation or reduction of oral anticoagulation to keep the INR in
the therapeutic range during the perioperative period.
In the past, continuing anticoagulation throughout the perio-
perative period was perceived to increase the risk of bleeding
complications. Recent studies, however, have challenged this
concern and suggested that there was no greater risk of bleeding
by maintaining therapeutic warfarin than simply withholding
warfarin during the implantation period.4. Risk of thromboembolism with short-term interruption of
warfarin therapy
A systematic review of perioperative anticoagulation suggested
that risk of stroke for patients in whom warfarin was withheld
might be substantially higher than would be predicted based on
annual thromboembolic rates of patients with atrial ﬁbrillation or a
mechanical heart valve [5]. In a prospective, observational cohort
study, 1293 episodes of warfarin therapy interruption in 1024
patients for an outpatient invasive procedure were included [6].
Warfarin therapy was withheld for r5 days in 83.8% of the
episodes. Seven patients (0.7%) experienced postprocedural throm-
boembolic events. All those patients with arterial events were in
atrial ﬁbrillation with CHADS2 score of Z2. In our study, 114
patients on chronic warfarin therapy had anticoagulation tempora-
rily interrupted for CIED surgery without bridging therapy. Among
them, 4 patients with atrial ﬁbrillation and CHADS score Z3
experienced a transient ischemic attack (TIA) even though these
patients continued to receive aspirin [7]. Although it is generally
safe for low risk patients, a short period of interruption of warfarin
therapy during the periprocedural period in patients with moder-
ate to high risk factors could potentially expose them to a small,
but real thromboembolic threat.5. Risk of pocket hematoma on bridging therapy with heparin
or LMWH
A substantial risk of pocket hematoma related to bridging
therapy with therapeutic dose of heparin or LMWH has been
consistently observed in patients undergoing device surgery. In a
retrospective cohort study, Wiegand et al. reported that patients
who received bridging therapy, with a therapeutic dose of heparin,
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the group who did not receive such treatment (10.7% vs. 2.9%;
po0.001) [8]. In a randomized trial, Michaud et al. demonstrated up
to 10-fold greater risk of pocket hematoma after device implantation
in patients who received intravenous heparin than in patients who
did not receive such therapy [9]. The risk was similar whether
heparin therapy was initiated 6 h or 24 h after surgery. Marquie
et al. conﬁrmed that the postoperative use of heparin of any type
conferred a 14-fold increased risk for pocket hematoma [10]. Similar
ﬁndings were reported by us and other authors [7,11]. Robinson
et al. showed that omission of LMWH the night before procedure did
not reduce hematoma rates, but omission of postoperative LMWH
dramatically reduced the occurrence of hematoma [12].
Several studies also demonstrated that bridging therapy is
associated with a longer hospital stay after the procedure
[7,13,14]. This ﬁnding is expected, as a patient on bridging
therapy with intravenous heparin must be kept in the hospital
until their INR reaches the therapeutic range. Although subcuta-
neous LMWH could be self-administered, many of these patients
were unable to do so and required transfer to a transitional
facility. In addition, patients who developed a pocket hematoma
stayed in the hospital longer for observation, transfusion, or
surgical evacuation [15]. More importantly. the development of
pocket hematoma often lead to withhold anticoagulation therapy
for a prolonged time and thus potentially increase the risk for
thromboembolism in these patients.6. Safety of continuation of warfarin during the perioperative
period of pacemaker and deﬁbrillator surgery
An increasing body of literature has suggested that pacemaker
and deﬁbrillator implantation without cessation of oral antic-
oagulation is safe and feasible. Goldstein et al. were among the
ﬁrst to report their experience implanting devices in 37 patients
continued on warfarin with a mean INR of 2.5 at the time of device
surgery and compared to 113 patients who did not receive
warfarin. The incidence of pocket hematoma in warfarin continua-
tion group was not signiﬁcantly different from the controls [16].
Al-Khadra reported similar ﬁndings in 47 patients with a mean INR
2.3 at device implantation [17]. Only 1 patient in his study had a
small hematoma, which resolved spontaneously. The largest obser-
vational study was provided by Giudici et al. who assessed the risk
of major bleeding complications in 1025 patients undergoing
pacemaker or ICD implantation, 470 of whom were continued on
warfarin therapy (mean INR 2.5, range 1.5 to 7.5) [18]. They found
similar complication rates between patients continued on warfarin
therapy and patients who had a normal INR while warfarin wasTable 2
Postoperative hemorrhagic and thromboembolic complications in 459 patients on
chronic warfarin therapy managed by three perioperative strategies
Outcome Continued warfarin
(n¼222)
Bridging
(n¼123)
Anticoagulation
withheld (n¼114)
Hematoma 1 (0.45%) 7 (5.7%) 2 (1.75%)
p¼ .004 p¼ .26
Transient
ischemic
attack
0 1 (0.8%) 4 (3.5%)
p¼ .35 p¼ .01
Mean INR (7SD) 2.5770.49 1.3370.20 1.3570.32
INR range 1.5–4.7 1.1–1.7 1.0–1.6
INR¼ International normal ratio.
Source: Table reproduced with permission from Heart Rhythm Society.withheld. Cheng et al. randomized 100 patients undergoing pace-
maker and deﬁbrillator implantation into a warfarin continued
group and a warfarin interrupted group [19]. Of warfarin inter-
rupted group, 7 patients received bridging with heparin and 43
patients received no bridging therapy. Two patients developed
pocket hematoma in bridging group and one patient had TIA in no
bridging group. No events were noted in warfarin continued group.
Li et al. retrospectively studied 766 patients on chronic warfarin
therapy who underwent device-related procedures [13]. Patients
were divided into three groups: discontinued warfarin, continued
warfarin, and discontinued warfarin with heparin bridging. Bleed-
ing events occurred more often in the heparin bridging group
(7.0%) than the discontinued warfarin group (2.1%) or continued
warfarin group (3.7%, p¼0.029). Concurrent aspirin use with
warfarin signiﬁcantly increased bleeding risk than warfarin alone
(5.6% vs. 1.4%, p¼0.02). We performed a retrospective analysis of
459 consecutive patients on chronic warfarin therapy who under-
went CIED surgery [7]. Warfarin was continued in 222 patients,
discontinued with heparin or LMWH bridging in 123 patients, and
temporarily discontinued without bridging therapy in 114 patients.
The perioperative pocket hematoma and thromboembolic compli-
cations in these patients are shown in Table 2. Patients who
continued warfarin had a lower incidence of pocket hematoma
than did patients in the bridging group. Holding warfarin without
bridging was associated with a higher incidence of transient
ischemic attacks than those on continued warfarin. Similar
ﬁndings were observed by other authors [20]. Only two small
studies failed to show a negative impact of bridging therapy
[21,22]. Two recent articles used a meta-analysis to compare
various strategies in the perioperative management of anticoagu-
lation therapy in patients undergoing CIED surgery. Bernard et al.
analyzed bleeding complications of 5978 patients from 11 studies
and found that the estimated odds of bleeding increased by
8.3 times in patients with heparin bridging, 5 times for dual
antiplatelet therapy (DAPT) compared to 1.6 times for continued
oral anticoagulation [23]. The authors concluded that continuation
of oral anticoagulation did not increase bleeding events compared
to no anticoagulation therapy. The meta-analysis by Ghanbari et el
evaluated 2321 patients undergoing implantation of CIED from
8 studies and found that continuation of therapeutic warfarin
therapy was associated with lower risk of bleeding compared to
heparin-based bridging therapy without increasing risk for throm-
boembolic events [24].7. Safety of cardiac resynchronization therapy device
implantation with continuation of warfarin
Many patients requiring cardiac resynchronization therapy
(CRT) are on chronic warfarin therapy. Although previous studies
have suggested that placement of pacemaker or implantable
deﬁbrillator in patients with continuation of oral anticoagulation
is safe, the safety of this approach in patients for CRT device
surgery has not been well established. A speciﬁc concern is the
potential serious bleeding consequence if coronary sinus (CS)
dissection or perforation occurred during placement of a left
ventricular (LV) lead. Fortunately, coronary venous perforation
during the procedure is rare [25]. We retrospectively analyzed 90
consecutive patients on chronic warfarin therapy who underwent
CRT device implantation at our institution [26]. Warfarin therapy
was continued in 65 patients, interrupted with bridging in 10
patients and without bridging in 15 patients. A LV lead was
successfully implanted in 92% of patients. Pre-procedural mean
INR was 2.570.38 in patients with continued warfarin. CS
dissection occurred in four patients: 3 in patients with continued
warfarin and 1 with warfarin discontinued without bridging. CS
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placement nor did it lead to pericardial effusion or tamponade even
when INR were in the therapeutic range. Clinically signiﬁcant pocket
hematoma occurred in two patients: one was on heparin bridging
and one without bridging but was on DAPT. One patient with
discontinued warfarin had a TIA. None of the 65 patients on
continued warfarin therapy had bleeding or thromboembolic events.
Ghanbari et al. reported the incidence of pocket hematoma in
patients undergoing CRT device implantation was 5% in the 20
patients with uninterrupted warfarin as compared to 20.7% in the 29
patients who received bridging therapy (p¼0.03) [27]. No patient
had pericardial effusion. Although published data are limited, CRT
device implantation with continuation of warfarin appears to be
safe, with a low risk of bleeding complications [28].8. Risk of bleeding complications with dual antiplatelet agents
Dual antiplatelet therapy (DAPT) with combined aspirin and
clopidogrel has become a standard treatment after percutaneous
coronary intervention (PCI). Recent studies have examined the
impact of such therapy on the incidence of bleeding complications
after CIED surgery. Dreger et al. did not notice an increased risk of
clinically relevant hematoma when a drainage system was applied
[29]. However, several other studies have demonstrated a consis-
tently higher risk of bleeding complications in these patients.
Wiegand et al. reported that the use of DAPT was highly predictive
for intraoperative bleeding and pocket hematoma in patients who
have undergone pacemaker and deﬁbrillator implantation, while
aspirin monotherapy did not appear to have a signiﬁcant impact on
bleeding complications [8]. Tompkins et al. demonstrated that
patients on DAPT had a signiﬁcantly increased bleeding risk as
compared with controls (7.2% vs. 1.6%; p¼0.004), while bleeding
risk was only marginally higher in patients taking aspirin
alone (3.9% vs. 1.6%, p¼0.078) [11]. Thal et al. noted that more
patients with hematoma were on DAPT than warfarin therapy alone,
and those with the highest incidence of hematoma (40%) were on
DAPT combined with warfarin [30]. Kutinsky et al. reported the
incidence of pocket hematoma after CIED surgery: aspirin 4.2%,
warfarin 6.9%, warfarinþaspirin 10.3%, clopidogrel11.1%, DAPT
24.2%, and warfarinþDAPT 9.5% [31]. Clopidogrel use was one of
the predictors of pocket hematoma, while aspirin monotherapy did
not seem to have a signiﬁcant impact on bleeding complications. In
the meta-analysis by Bernard et al., bleeding event rates were 2.2%
for no therapy, 2.5% for warfarin held, 2.8% for warfarin continued,
3.9% for single antiplatelet therapy, 9.4% for DAPT and 14.6% for
heparin bridging strategy (Fig. 1) [23].Fig. 1. Meta-analysis of unadjusted, pooled rates of bleeding complications
associated with CIED implantation. AC = anticoagulant; SAPT = single antiplatelet
therapy; DAPT = dual antiplatelet therapy; HBS = heparin bridging strategy
(Reproduced with permission of Circulation: Arrhythmia and Electrophysiology
from Ref. 23)9. Empirical approaches to reduce the perioperative bleeding
complications
We previously reported that chronic kidney disease was an
independent risk factor for pocket hematoma after CIED implanta-
tion, probably due to a higher bleeding tendency in these patients
[32]. A recent report from a prospective, multicenter registry con-
ﬁrmed that HAS-BLED score predicted bleedings during bridging
of chronic oral anticoagulation [33]. Such data are not available in
patients on continuous warfarin therapy undergoing CIED surgery.
There is hope that improvement in patient co-morbidities, by aggres-
sively treating the underlying diseases, will lead to a lower risk of
postoperative bleeding complications. It is important to coordinate
the timing of elective PCI and device surgery. Elective PCI should be
postponed if possible after device surgery to avoid DAPT in the
immediate postoperative period. Target vein venography could be
used more frequently if the patient has preserved renal function.
Contrast subclavian and auxillary venogram provides a clear anato-
mical picture and facilitates direct venopuncture [34]. We propose
the use of a micropuncture technique to reduce the severity of
bleeding in case of inadvertent arterial punctures [35]. A generator
pocket formed between the deep fascia and the pectoral muscle
probably has less bleeding risk than an intramuscular pocket,
however, there are no comparative data to draw clear conclusions.
Although the ﬁbrous capsule surrounding the CIED generator often
has ample vascular supply and may prone to bleed than new
implantation, there is no controlled study available for comparison.
In a multicenter prospective study of complications related to CIED
generator replacement, Pooles et al. reported the rates of hematoma
requiring surgical evacuation were 0.7% in patients had generator
change only and signiﬁcantly higher at 1.5% in those with upgrade
and transvenous lead additions [36]. Careful intraoperative hemos-
tasis is crucial, especially if the patient is on the continued warfarin
therapy. We usually avoid the practice of temporary placement of
gauzes into the pocket during the operation to decrease the risk of
delayed bleeding and hematoma formation after pocket closure.
Application of sterile pressure dressings on the wound is a common
practice although its duration and effectiveness have not been
studied. Finally, the practice of sealants injected into the pocket
before incision closure remains to be controversial [21,37].10. Practical management of perioperative anticoagulation
and antiplatelet therapy in CIED surgery
By integrating the current literature and the experience from
our own practice, we developed a practical algorithm recently
to guide the perioperative management of anticoagulation and
antiplatelet therapy in patients on warfarin therapy undergoing
CIED surgery (Fig.2). Because patients may have coexisting risk
factors for bleeding such as liver disease, renal dysfunction or
bleeding tendencies, the actual situation may be more complex.
A decision should be made based on baseline risk and the
individual patient factors. Different protocols have been proposed
by the others [14,38]. Update is needed when the results of the
ongoing and future multicenter, randomized controlled clinical
trials become available [39]. At this time, there are no data with
the newer generation of anticoagulants such as dabigatran,
rivaroxaban, and apixaban in the settings of CIED surgery.
For most patients with a low risk for thromboembolism, such as
atrial ﬁbrillation with CHADS2r1 or remote deep venous throm-
bosis (DVT), warfarin could be withheld for 2–3 days before surgery
and then resumed in the same day after surgery. One exception to
this strategy is in patients with atrial ﬁbrillation undergoing ICD
surgery involving deﬁbrillation threshold testing. Since deﬁbrillation
Fig. 2. Practical algorithm for the perioperative management of anticoagulation and antiplatelet therapy in surgery of cardiac implantable electronic devices. ASA, Aspirin;
BMS, Bare Metal Stent; CRT Cardiac Resynchronization Therapy; DAPT, Dual Antiplatelet Therapy; DES, Drug Eluting Stent; ICD, Internal Cardioverter Deﬁbrillator; PPM
Permanent Pacemaker; TE, Thromboembolism.
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uninterrupted warfarin therapy with therapeutic INR.
For patients with moderate to high risks for thromboembolism,
such as mechanical valves, atrial ﬁbrillation with mitral stenosis or
CHADS2Z2, or recent deep venous thrombosis, CIED surgery
including LV lead placement appears to be safe and cost effective
with the strategy of continuing warfarin therapy with therapeutic
INR as compared to bridging therapy or temporarily withholding
anticoagulation.
Increasing evidence suggests that perioperative bridging therapy,
with intravenous heparin or IMWH, signiﬁcantly increases the risk of
pocket hematoma after CIED surgery. This practice is also associated
with higher costs, complexity of procedure scheduling and a longer
hospital stay. Therefore, we believe that this strategy should not be
recommended to most patients undergoing CIED surgery.
DAPT could increase the risk of intraoperative bleeding and
pocket hematoma. On the other hand, DAPT prevents stent throm-
bosis which is a devastating complication with a high morbidity and
mortality. In patients who require urgent device surgery within
6 weeks of placement of a bare-mental stent or within 6–12 months
of placement of a drug-eluting stent, we suggest to continue DAPT
around the time of device surgery while applying hemostasis
measures carefully and observing these patients closely. For CIED
surgery beyond that critical period in patients with stent(s), aspirin
therapy should be continued while clopidogrel may be withhold
7 days prior to the surgery to reduce the risk of bleeding especially if
the patient is also on concurrent warfarin therapy.
Aspirin monotherapy does not seem to have a signiﬁcant
impact on bleeding complications and can be continued safely
during the surgery. Concurrent aspirin use with warfarin has been
associated with signiﬁcantly higher bleeding risk than warfarin
alone. On the other hand, clopidogrel monotherapy seems be
predictive of pocket hematoma, and may be held temporarily.
If the purpose of aspirin or clopidogrel use is for primary prevention
of cardiovascular disease, it may be reasonable to temporarily
withhold these agents if concurrent warfarin therapy is continued
during the perioperative period.Conﬂict of interest
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